Valgimigli et al. found that P2Y12 inhibitor monotherapy was associated with a similar risk of death, myocardial infarction, or stroke, with evidence that this association may be modified by gender, and a lower bleeding risk compared with DAPT [31]. Here, P2RY12 is linked to stroke disorder.